Wave Life Sciences starts Phase 2a trial of WVE-007 with tirzepatide for obesity
WVE•Preclinical and clinical context
Earlier preclinical results were presented at ObesityWeek 2025, supporting greater weight loss in combination than with GLP-1 therapy alone.
Clinical data to date suggest fat loss without muscle loss, supporting an infrequent dosing approach for WVE-007.
A separate maintenance study to limit weight regain after stopping incretin therapy is slated to start in 2H 2026.
Phase 2a trial begins with tirzepatide combination
Wave Life Sciences launched a Phase 2a trial testing WVE-007 with weekly tirzepatide in adults with obesity and type 2 diabetes.
The study expands WVE-007 into combination use, a key step toward broader positioning across obesity and related cardiometabolic indications.
